论文部分内容阅读
目的观察吉非替尼在肺癌治疗中的疗效分离现象。方法回顾分析90例非小细胞肺癌患者的临床资料,患者均给予吉非替尼治疗,观察患者治疗中的疗效分离现象。结果 90例患者发生分离现象12例,占13.33%。5例出现部分病灶不均匀改变,其中3例部分病灶缩小、1例部分病灶无变化、1例部分病灶扩大;4例发生肺癌原发病灶转移,其中2例为骨转移、2例为淋巴转移。定期复查时发现新病灶,及时有效治疗后病情控制;3例出现脑转移病灶扩大。结论非小细胞癌患者行吉非替尼治疗,其疗效分离现象具有常见性,在日后研究中应关注吉非替尼在肺癌治疗中疗效分离现象的分子机制与治疗策略。
Objective To observe the effect of gefitinib in the treatment of lung cancer separation phenomenon. Methods The clinical data of 90 patients with non-small cell lung cancer were retrospectively analyzed. All patients were treated with gefitinib to observe the therapeutic effect separation in patients. Results 90 cases of patients with segregation occurred in 12 cases, accounting for 13.33%. In 5 cases, partial lesions were not uniformly changed, of which 3 cases had partial lesion shrinking, 1 case partial lesion did not change, 1 case partial lesion enlarged, 4 cases primary lung cancer metastasis, 2 cases bone metastasis and 2 cases lymphatic metastasis . Periodic review found new lesions, the timely and effective treatment of disease control; 3 cases of brain metastasis lesions expanded. Conclusion Gefitinib treatment of non-small cell lung cancer patients, the efficacy of the phenomenon of separation is common in future studies should pay attention to the mechanism of gefitinib in the treatment of lung cancer in the molecular mechanism of treatment and treatment strategies.